More Positive Amarin Developments This Week
Growth, Value
Seeking Alpha Analyst Since 2012
While multiple followers have emailed me about some comments by someone named Jeerio re: FDA allowing JELIS data to be included when marketing Vascepa, I have no information to contribute whether that is fact or fiction. While it would seem positive, I would tread carefully with that information.
I will say I have been able to confirm that Vascepa will have expanded label data by end of this year, based on enrollment >50% for Reduce-It. This is very significant and if WallStreet actually got their heads out of their bums, the stock would trade up $3-5 on this expectation alone...
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.